Brief: Guard Therapeutics RMC-035 Development Plan Receives Positive Feedback From FDA
Jan 15 (Reuters) - Guard Therapeutics International AB (publ) GUARD.ST :
* FDA PROVIDES POSITIVE FEEDBACK TO GUARD THERAPEUTICS REGARDING THE CONTINUED DEVELOPMENT
PLAN
FOR RMC-035
Source text for Eikon: ID:nMFN2Gh0tl
Further company coverage: GUARD.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Disruptive Pharma AB (publ)
See all newsBrief: Disruptive Pharma To Sell GTX Platform To Aurelia Invest AB Unit
Brief: Guard Therapeutics International Q2 Loss Before Tax SEK 4.4 Mln
Brief: Guard Therapeutics Gets Conditional Approval For Continued Listing
Brief: Guard Therapeutics International Initiates Deal Process For Gtx Platform
Brief: Guard Therapeutics Enters Conditional Deal For Reverse Takeover